Turn Therapeutics Inc. (NASDAQ:TTRX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Turn Therapeutics, with two strong-buy, one buy, one hold and two sell ratings. The average 12-month price target is $9.00.
• Institutional investors including BlackRock, Bridgewater Advisors, Jefferies and Bank of America recently established positions in the company, with reported purchases ranging from approximately $103,000 to $282,000.
• TTRX opened at $11.39, with a market capitalization of about $339 million and a share price ranging from $2.57 to $26.50 over the past year. The company reported a quarterly loss of $0.20 per share and analysts expect a full-year loss of $0.40 per share.

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.00.

TTRX has been the subject of several recent analyst reports. Zacks Research upgraded Turn Therapeutics to a "hold" rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a report on Monday, July 20th. Wall Street Zen cut Turn Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, September 26th. WBB Securities reaffirmed a "sell" rating and set a $10.00 target price on shares of Turn Therapeutics in a research report on Monday, September 14th. Finally, Lucid Cap Mkts upgraded Turn Therapeutics to a "strong-buy" rating in a report on Thursday, September 24th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE acquired a new position in Turn Therapeutics during the 2nd quarter worth $103,000. Tamar Securities LLC bought a new stake in Turn Therapeutics during the fourth quarter valued at about $59,000. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at about $119,000. Bridgewater Advisors Inc. bought a new position in shares of Turn Therapeutics in the second quarter worth about $242,000. Finally, BlackRock Inc. bought a new position in shares of Turn Therapeutics in the second quarter worth about $282,000.

Turn Therapeutics Stock Down 5.9%

TTRX stock opened at $11.39 on Friday. The firm has a market cap of $339.31 million and a PE ratio of -39.28. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The company has a fifty day simple moving average of $11.38 and a 200 day simple moving average of $7.60. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Sell-side analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.